|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.72 0.0005 0.0034%
Dr. Geoffrey McDonough, M.D. no longer serves as President and Chief Executive Officer of Swedish Orphan Biovitrum AB effective as of July 1, 2017. He has held the position since August 15, 2011. He is also Board member of Zafgen and PTC Therapeutics. He previously served for Genzyme Corporationrationration in the United States from 2002, where he has over the years held such roles as Senior Vice President and General Manager, Personalized Genetic Health Senior Vice President, Global Business Unit Leader, LSD Therapeutics, and most recently, President of Europe, Middle East, and Africa . Prior to joining Genzyme, he worked as a pediatrician in the United States, and was also President, and Cofounder of Catalyst Medical Solutions Inc. He graduated from Harvard Medical School with a Medical Doctor degree. He holds a Bachelor of Arts in Philosophy and a BS in Biology degrees from the University of North Carolina.
Age: 44 CEO Since 2011 Ph.D
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 6.58 %
which means that it generated profit of $6.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 14.88 %
meaning that it generated $14.88 on every $100 dollars invested by stockholders.
The company has accumulated 60.96 M in total debt with debt to equity ratio (D/E) of 7.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.78 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.